Prognostic value of cytogenetic analysis in clear cell renal carcinoma: A study on 131 patients with long-term follow-up

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4705-4709

  Antonelli, Alessandro ^a   Arrighi, Nicola ^a   Tardanico, Regina ^a   Balzarini, Piera ^a   Zanotelli, Tiziano ^a   Corti, Serena ^a   Zani, Danilo ^a   Cozzoli, Alberto ^a   Cunico, Sergio Cosciani ^a   Simeone, Claudio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Chromosome alterations; Clear cell renal carcinoma; Karyotype analysis; Progosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 19; CHROMOSOME 20; CHROMOSOME 22; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLEAR CELL CARCINOMA; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; KARYOTYPE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NEPHRECTOMY; NEPHRON SPARING SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; THORAX RADIOGRAPHY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARYOTYPING; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 78650245234     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kovacs G, Akthar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E and Zbar B: The Heildelberg classification of renal cell tumours. J Pathol 183: 131-133, 1997.
2. Limon J, Dal Cin P and Sandberg AA: Application of long-term collagenase disaggregation for cytogenetic analysis of human solid tumors. Cancer Genet Cytogenet 23: 305-313, 1986.
3. International Standing Committee on Human Cytogenetic Nomenclature: ISCN 2005: An international system for human cytogenetic nomenclature - Recommendations of International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 2005.
4. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
5. Soung Sullivan P, Rao J, Cheng L and Cote RJ: Classical pathology versus molecular pathology in renal cell carcinoma. Curr Urol Rep 8: 5-11, 2007. (Pubitemid 46202653)
6. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS and Pantuck AJ: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23: 2763-2771, 2005.
7. Van der Berg E, Van der Hout AH, Oosterhuis JW, Störkel S, Dijkhuizen T, Dam A, Zweers HM, Mensink HJ, Buys CH and de Jong B: Cytogenetic analysis of epithelial renal cell tumors: relationship with a new histopathological classification. Int J Cancer 55: 223-227, 1993.
8. Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ and Figlin RA: Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol 65: 235-236, 2008.
9. Schulleras D, Herbers J, Chudek J, Bugert P, Kanamara H, Zeisler J, Ljungberg B, Akhtar M and Kovacs G: Loss of heterozigosity at chromosome 8p, 9p and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 183: 151-155, 1997.
10. Elfving P, Mandahal N, Lundgren R, Limon J, Bak-Jensen E, Fernö M, Olsson H and Mitelman F: Prognostic implications of cytogenetic findings in kidney cancer. Br J Urol 80: 698-706, 1997.
11. Moch H, Presti JC Jr., Sauter G, Buchholz N, Jordan P, Mihatsch MJ and Waldman FM: Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56: 27-30, 1996. (Pubitemid 26010380)
12. Beroud C, Fournet JC, Jeanpierre C, Droz D, Bouvier R, Froger D, Chrétien Y, Maréchal JM, Weissenbach J and Junien C: Correlations of allelic imbalance of chromosome 14 with adverse prognostic parameters in 148 renal cell carcinomas. Genes Chromosomes Cancer 17: 215-224, 1996.
13. Wu SQ, Hafez GR, Xing W, Newton M, Chen XR and Messing E: The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma. Cancer 77: 1154-1160, 1996.
14. Alimov A, Sundelin B, Wang N, Larsson C and Bergerheim U: Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol 25: 179-185, 2004.
15. Brunelli M, Eccher A, Gobbo S, Ficarra V, Novara G, Cossu-Rocca P, Bonetti F, Menestrina F, Cheng L, Eble JN and Martignoni GI: Loss of chromosome 9p is an independent prognostic factor in clear cell renal carcinoma. Mod Pathol 21: 1-6, 2008.
16. Gunawan B, Huber W, Holtrup M, von Heydebreck A, Efferth T, Poustka A, Ringert RH, Jakse G and Füzesi L: Prognostic impacts of cytogenetic findings in clear cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favourable prognosis. Cancer Res 61: 7731-7738, 2001.
17. Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS and Pantuck AJ: Cytogenetic profile predicts prognosis of patients with clear cell carcinoma. J Clin Oncol 27: 746-753, 2009.
18. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
19. Coppin C, Le L, Porzsolt F and Wilt T: Targeted therapy for advanced renal cell carcinoma. Cochrane Database of Systematic Reviews 2008, Issue 2.
20. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
21. Brugarolas J: Renal-cell carcinoma. Molecular pathways and therapies. N Eng J Med 356: 185-187, 2007.
22. Le Jan S, Amy C, Cazes A, Monnot C, Lamandé N, Favier J, Philippe J, Sibony M, Gase JM, Corvol P and Germain S: Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 162: 1521-1528, 2003.
23. Pantuck AJ, Zeng G, Belldegrun AS and Figlin RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9: 4641-4652, 2003.